Yayın: Pharmacokinetics and Bioavailability of Carprofen in Rainbow Trout (Oncorhynchus mykiss) Broodstock
| dc.contributor.author | Uney, Kamil | |
| dc.contributor.author | Durna Corum, Duygu | |
| dc.contributor.author | Terzi, Ertugrul | |
| dc.contributor.author | Corum, Orhan | |
| dc.date.accessioned | 2026-01-04T15:31:10Z | |
| dc.date.issued | 2021-06-30 | |
| dc.description.abstract | The aim of this study was to determine the pharmacokinetics of carprofen following intravenous (IV), intramuscular (IM) and oral routes to rainbow trout (Oncorhynchus mykiss) broodstock at temperatures of 10 ± 1.5 °C. In this study, thirty-six healthy rainbow trout broodstock (body weight, 1.45 ± 0.30 kg) were used. The plasma concentrations of carprofen were determined using high-performance liquid chromatography and pharmacokinetic parameters were calculated using non-compartmental analysis. Carprofen was measured up to 192 h for IV route and 240 h for IM, and oral routes in plasma. The elimination half-life (t1/2λz) was 30.66, 46.11, and 41.08 h for IV, IM and oral routes, respectively. Carprofen for the IV route showed the total clearance of 0.02 L/h/kg and volume of distribution at steady state of 0.60 L/kg. For IM and oral routes, the peak plasma concentration (Cmax) was 3.96 and 2.52 μg/mL with the time to reach Cmax of 2 and 4 h, respectively. The bioavailability was 121.89% for IM route and 78.66% for oral route. The favorable pharmacokinetic properties such as the good bioavailability and long t1/2λz for IM and oral route of carprofen suggest the possibility of its effective use for the treatment of various conditions in broodstock. | |
| dc.description.uri | https://doi.org/10.3390/pharmaceutics13070990 | |
| dc.description.uri | https://www.mdpi.com/1999-4923/13/7/990/pdf | |
| dc.description.uri | https://pubmed.ncbi.nlm.nih.gov/34208822 | |
| dc.description.uri | http://dx.doi.org/10.3390/pharmaceutics13070990 | |
| dc.description.uri | https://doaj.org/article/99c3155447f44c95a8de3314d5384072 | |
| dc.description.uri | https://dx.doi.org/10.3390/pharmaceutics13070990 | |
| dc.identifier.doi | 10.3390/pharmaceutics13070990 | |
| dc.identifier.eissn | 1999-4923 | |
| dc.identifier.openaire | doi_dedup___::187d25ecec539fb3c397564d75137ad8 | |
| dc.identifier.orcid | 0000-0002-8674-4873 | |
| dc.identifier.orcid | 0000-0003-1567-991x | |
| dc.identifier.orcid | 0000-0003-2811-6497 | |
| dc.identifier.orcid | 0000-0003-3168-2510 | |
| dc.identifier.pubmed | 34208822 | |
| dc.identifier.scopus | 2-s2.0-85109515725 | |
| dc.identifier.startpage | 990 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12597/38880 | |
| dc.identifier.volume | 13 | |
| dc.identifier.wos | 000676782300001 | |
| dc.language.iso | eng | |
| dc.publisher | MDPI AG | |
| dc.relation.ispartof | Pharmaceutics | |
| dc.rights | OPEN | |
| dc.subject | RS1-441 | |
| dc.subject | carprofen | |
| dc.subject | Pharmacy and materia medica | |
| dc.subject | broodstock | |
| dc.subject | bioavailability | |
| dc.subject | pharmacokinetics | |
| dc.subject | rainbow trout | |
| dc.subject | Article | |
| dc.subject.sdg | 3. Good health | |
| dc.title | Pharmacokinetics and Bioavailability of Carprofen in Rainbow Trout (Oncorhynchus mykiss) Broodstock | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.api.response | {"authors":[{"fullName":"Kamil Uney","name":"Kamil","surname":"Uney","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0002-8674-4873"},"provenance":null}},{"fullName":"Duygu Durna Corum","name":"Duygu","surname":"Durna Corum","rank":2,"pid":{"id":{"scheme":"orcid","value":"0000-0003-1567-991x"},"provenance":null}},{"fullName":"Ertugrul Terzi","name":"Ertugrul","surname":"Terzi","rank":3,"pid":{"id":{"scheme":"orcid","value":"0000-0003-2811-6497"},"provenance":null}},{"fullName":"Orhan Corum","name":"Orhan","surname":"Corum","rank":4,"pid":{"id":{"scheme":"orcid","value":"0000-0003-3168-2510"},"provenance":null}}],"openAccessColor":"gold","publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"RS1-441"},"provenance":null},{"subject":{"scheme":"FOS","value":"0301 basic medicine"},"provenance":null},{"subject":{"scheme":"FOS","value":"0403 veterinary science"},"provenance":null},{"subject":{"scheme":"keyword","value":"carprofen"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Pharmacy and materia medica"},"provenance":null},{"subject":{"scheme":"keyword","value":"broodstock"},"provenance":null},{"subject":{"scheme":"FOS","value":"04 agricultural and veterinary sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"bioavailability"},"provenance":null},{"subject":{"scheme":"keyword","value":"pharmacokinetics"},"provenance":null},{"subject":{"scheme":"keyword","value":"rainbow trout"},"provenance":null},{"subject":{"scheme":"keyword","value":"Article"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null}],"mainTitle":"Pharmacokinetics and Bioavailability of Carprofen in Rainbow Trout (Oncorhynchus mykiss) Broodstock","subTitle":null,"descriptions":["<jats:p>The aim of this study was to determine the pharmacokinetics of carprofen following intravenous (IV), intramuscular (IM) and oral routes to rainbow trout (Oncorhynchus mykiss) broodstock at temperatures of 10 ± 1.5 °C. In this study, thirty-six healthy rainbow trout broodstock (body weight, 1.45 ± 0.30 kg) were used. The plasma concentrations of carprofen were determined using high-performance liquid chromatography and pharmacokinetic parameters were calculated using non-compartmental analysis. Carprofen was measured up to 192 h for IV route and 240 h for IM, and oral routes in plasma. The elimination half-life (t1/2λz) was 30.66, 46.11, and 41.08 h for IV, IM and oral routes, respectively. Carprofen for the IV route showed the total clearance of 0.02 L/h/kg and volume of distribution at steady state of 0.60 L/kg. For IM and oral routes, the peak plasma concentration (Cmax) was 3.96 and 2.52 μg/mL with the time to reach Cmax of 2 and 4 h, respectively. The bioavailability was 121.89% for IM route and 78.66% for oral route. The favorable pharmacokinetic properties such as the good bioavailability and long t1/2λz for IM and oral route of carprofen suggest the possibility of its effective use for the treatment of various conditions in broodstock.</jats:p>"],"publicationDate":"2021-06-30","publisher":"MDPI AG","embargoEndDate":null,"sources":["Crossref","Pharmaceutics","Pharmaceutics, Vol 13, Iss 7, p 990 (2021)","Volume 13","Issue 7"],"formats":["application/pdf"],"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Pharmaceutics","issnPrinted":null,"issnOnline":"1999-4923","issnLinking":null,"ep":null,"iss":null,"sp":"990","vol":"13","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::187d25ecec539fb3c397564d75137ad8","originalIds":["pharmaceutics13070990","10.3390/pharmaceutics13070990","50|doiboost____|187d25ecec539fb3c397564d75137ad8","od_______267::e6d32b82dfdb7debdfc74f4aa5c98e86","34208822","PMC8309133","50|od_______267::e6d32b82dfdb7debdfc74f4aa5c98e86","oai:pubmedcentral.nih.gov:8309133","oai:doaj.org/article:99c3155447f44c95a8de3314d5384072","50|doajarticles::fe54ff34fb4d2a9a369fbde31f0eb1c1","3176761491","50|multidiscipl::1efdd76a1955b9704be6e0005ee6e11f","oai:mdpi.com:/1999-4923/13/7/990/"],"pids":[{"scheme":"doi","value":"10.3390/pharmaceutics13070990"},{"scheme":"pmid","value":"34208822"},{"scheme":"pmc","value":"PMC8309133"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":20,"influence":3.3351137e-9,"popularity":1.7355255e-8,"impulse":14,"citationClass":"C4","influenceClass":"C4","impulseClass":"C4","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.3390/pharmaceutics13070990"}],"license":"CC BY","type":"Article","urls":["https://doi.org/10.3390/pharmaceutics13070990"],"publicationDate":"2021-06-30","refereed":"peerReviewed"},{"pids":[{"scheme":"doi","value":"10.3390/pharmaceutics13070990"}],"license":"CC BY","type":"Article","urls":["https://www.mdpi.com/1999-4923/13/7/990/pdf"],"refereed":"nonPeerReviewed"},{"pids":[{"scheme":"pmid","value":"34208822"},{"scheme":"pmc","value":"PMC8309133"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.3390/pharmaceutics13070990"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/34208822"],"refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.3390/pharmaceutics13070990"}],"license":"CC BY","type":"Other literature type","urls":["http://dx.doi.org/10.3390/pharmaceutics13070990"],"publicationDate":"2021-06-30","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.3390/pharmaceutics13070990"}],"type":"Article","urls":["https://doaj.org/article/99c3155447f44c95a8de3314d5384072"],"publicationDate":"2021-06-01","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.3390/pharmaceutics13070990"},{"scheme":"mag_id","value":"3176761491"}],"type":"Article","urls":["https://dx.doi.org/10.3390/pharmaceutics13070990"],"refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.3390/pharmaceutics13070990"}],"license":"CC BY","type":"Other literature type","urls":["http://dx.doi.org/10.3390/pharmaceutics13070990"],"publicationDate":"2021-06-30","refereed":"nonPeerReviewed"}],"isGreen":true,"isInDiamondJournal":false} | |
| local.import.source | OpenAire | |
| local.indexed.at | WOS | |
| local.indexed.at | Scopus | |
| local.indexed.at | PubMed |
